JP2019516392A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516392A5
JP2019516392A5 JP2018567013A JP2018567013A JP2019516392A5 JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5 JP 2018567013 A JP2018567013 A JP 2018567013A JP 2018567013 A JP2018567013 A JP 2018567013A JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5
Authority
JP
Japan
Prior art keywords
seq
constant domain
ilt7
item
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567013A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979976B2 (ja
JP2019516392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021616 external-priority patent/WO2017156298A1/en
Publication of JP2019516392A publication Critical patent/JP2019516392A/ja
Publication of JP2019516392A5 publication Critical patent/JP2019516392A5/ja
Priority to JP2021186637A priority Critical patent/JP7354212B2/ja
Application granted granted Critical
Publication of JP6979976B2 publication Critical patent/JP6979976B2/ja
Priority to JP2023151943A priority patent/JP7700190B2/ja
Priority to JP2025101902A priority patent/JP2025134836A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567013A 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法 Active JP6979976B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021186637A JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10
US62/306,125 2016-03-10
PCT/US2017/021616 WO2017156298A1 (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021186637A Division JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019516392A JP2019516392A (ja) 2019-06-20
JP2019516392A5 true JP2019516392A5 (https=) 2020-04-16
JP6979976B2 JP6979976B2 (ja) 2021-12-15

Family

ID=59790876

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567013A Active JP6979976B2 (ja) 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Country Status (16)

Country Link
US (3) US11072652B2 (https=)
EP (1) EP3426298A4 (https=)
JP (4) JP6979976B2 (https=)
KR (5) KR20250051802A (https=)
CN (2) CN109414499B (https=)
AR (2) AR109450A1 (https=)
AU (2) AU2017231833B2 (https=)
CA (1) CA3017197A1 (https=)
IL (2) IL321334A (https=)
MX (2) MX2018010771A (https=)
RU (1) RU2756109C2 (https=)
SG (2) SG10202008769SA (https=)
TW (1) TWI755380B (https=)
UA (1) UA127731C2 (https=)
WO (1) WO2017156298A1 (https=)
ZA (1) ZA201806597B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756109C2 (ru) * 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
WO2020214937A1 (en) * 2019-04-19 2020-10-22 Allogene Therapeutics, Inc. Antibodies against 4g7-derived chimeric antigen receptors
WO2021113702A1 (en) * 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
JP7822313B2 (ja) * 2019-12-20 2026-03-02 メディミューン,エルエルシー グリピカン3を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
WO2021203013A2 (en) * 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
IL308132A (en) 2021-05-04 2023-12-01 Viela Bio Inc Methods of treatment of autoimmune disorders using ilt7 binding proteins
AU2023312911A1 (en) 2022-07-27 2025-01-02 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN120435497A (zh) 2022-12-12 2025-08-05 维埃拉生物股份有限公司 用于治疗和预防肌炎的抗ilt7结合剂
KR20250160358A (ko) * 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (de) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
TWI335336B (https=) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA3077873A1 (en) 2002-03-20 2003-10-02 Catalina Marketing Corporation Targeted incentives based upon predicted behavior
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
HRP20130494T1 (en) 2005-12-20 2013-08-31 Sbi Biotech Co., Ltd. Anti-ilt7 antibody
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20110311558A1 (en) 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
AU2012249601A1 (en) 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
PT3415619T (pt) 2011-04-28 2021-03-22 Univ Leland Stanford Junior Identificação de polinucleótidos associados a uma amostra
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
EP3431504B1 (en) * 2012-01-31 2021-03-24 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
SG11201701529YA (en) 2014-08-29 2017-03-30 Sorrento Therapeutics Inc Antibody therapeutics that bind oprf and oprl
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
WO2021113702A1 (en) 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
IL308132A (en) 2021-05-04 2023-12-01 Viela Bio Inc Methods of treatment of autoimmune disorders using ilt7 binding proteins

Similar Documents

Publication Publication Date Title
JP2019516392A5 (https=)
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
CN112135626A (zh) 抗tigit抗体及其用途
CN110536903A (zh) 抗ox40抗体及其用途
WO2016000619A1 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
JP2020508655A5 (https=)
JP2014509861A5 (https=)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
CN113874400A (zh) 抗Vβ17/抗CD123双特异性抗体
JP2012526558A5 (https=)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2018135550A (ru) Связывающие ilt7 молекулы и способы их применения
CN109721656B (zh) 靶向rankl的治疗性抗体
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2019528046A5 (https=)
RU2019103991A (ru) Анти-il-22r-антитела
RU2020128108A (ru) Антитело против cd25 для опухоль-специфической клеточной деплеции
JPWO2021213475A5 (https=)
JP2021513357A5 (https=)
JPWO2023078382A5 (https=)
AU2021231712A1 (en) Anti-CD19 antibodies and methods of using and making thereof
JPWO2022218380A5 (https=)
WO2024088342A1 (en) Antibodies against cd24 and uses thereof
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения